CMA helps extend Aspen’s EU commitments to UK following Brexit

Aspen has agreed that price reductions it offered the European Commission in 2019 to end an excessive pricing probe into certain cancer treatments should also apply to the UK’s National Health Service following the country’s exit from the EU.

Get unlimited access to all Global Competition Review content